Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Wen-jun Chai"'
Autor:
Song-Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wen-Tao Yang, Wen-Jun Chai, Xiao-Mao Guo, Xi-Zi Chen, Yan-Hui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-15 (2022)
Abstract Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only a subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. Herei
Externí odkaz:
https://doaj.org/article/e0dbceec56ca46efaf601443a7bfe647
Autor:
Wen-feng Wei, Hui Sun, Shao-bo Liu, Sheng-wen Lu, Ai-hua Zhang, Wan-ying Wang, Wen-jun Chai, Fang-fang Wu, Guang-li Yan, Yu Guan, Xi-jun Wang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Damp-heat jaundice syndrome (DHJS) is a diagnostic model of traditional Chinese medicine (TCM) that refers to jaundice caused by damp-heat pathogen invasion. DHJS is the most common clinical manifestation of TCM, with yellow skin, yellow
Externí odkaz:
https://doaj.org/article/ac822678e0804b24b25304dbeec1f943
Autor:
Song-Yang Wu, Si-Wei Zhang, Ding Ma, Yi Xiao, Yin Liu, Li Chen, Xiao-Qing Song, Xiao-Yan Ma, Ying Xu, Wen-Jun Chai, Xi Jin, Zhi-Ming Shao, Yi-Zhou Jiang
Publikováno v:
Med.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4405c2646655326687c06d7f849fbea
https://doi.org/10.1016/j.medj.2023.04.008
https://doi.org/10.1016/j.medj.2023.04.008
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf9dd20e1c2e70c6f874ea9cfec3cb9
https://doi.org/10.1158/1078-0432.22487412.v1
https://doi.org/10.1158/1078-0432.22487412.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5866ab4f3e90784a490b8e46ab2dcc
https://doi.org/10.1158/1078-0432.22487397.v1
https://doi.org/10.1158/1078-0432.22487397.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2309b0f1682e17911f052505f61db101
https://doi.org/10.1158/1078-0432.22487400.v1
https://doi.org/10.1158/1078-0432.22487400.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Purpose:Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0933947e0d4bbbf77ca8537a0f12d16e
https://doi.org/10.1158/1078-0432.c.6532512.v1
https://doi.org/10.1158/1078-0432.c.6532512.v1
Autor:
Peng Ji, Yue Gong, Ming-liang Jin, Huai-liang Wu, Lin-Wei Guo, Yu-Chen Pei, Wen-Jun Chai, Yi-Zhou Jiang, Yin Liu, Xiao-Yan Ma, Gen-Hong Di, Xin Hu, Zhi-Ming Shao
Publikováno v:
Science Advances. 8
Immune checkpoint inhibitors exhibit limited response rates in patients with triple-negative breast cancer (TNBC), suggesting that additional immune escape mechanisms may exist. Here, we performed two-step customized in vivo CRISPR screens targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efc180a2bd79809319390166da8e7339
https://doi.org/10.1126/sciadv.abl8247
https://doi.org/10.1126/sciadv.abl8247